Cargando…

Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies

A novel clinical assay for the detection and quantitation of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was adapted from an in-house, research-based enzyme-linked immunosorbent assay (ELISA). Development and validation were performed under regulatory guidelines,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Żak, Magdalena M., Stock, Aryeh, Stadlbauer, Daniel, Zhang, Wei, Cummings, Kirstie, Marsiglia, William, Zargarov, Arsen, Amanat, Fatima, Tamayo, Monica, Cordon-Cardo, Carlos, Krammer, Florian, Mendu, Damodara Rao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605824/ https://www.ncbi.nlm.nih.gov/pubmed/34841098 http://dx.doi.org/10.1016/j.heliyon.2021.e08444

Ejemplares similares

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
por: Wajnberg, Ania, et al.
Publicado: (2020)

Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model
por: Stadlbauer, Daniel, et al.
Publicado: (2018)

Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms
por: Carreño, Juan Manuel, et al.
Publicado: (2021)

Binding and Avidity Signatures of Polyclonal Sera From Individuals With Different Exposure Histories to Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Vaccination, and Omicron Breakthrough Infections
por: Singh, Gagandeep, et al.
Publicado: (2023)

Creating surveillance data infrastructure using laboratory analytics: Leveraging visiun and epic systems to support COVID-19 pandemic response
por: Haghighi, Mehrvash, et al.
Publicado: (2022)

Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin
por: Rajendran, Madhusudan, et al.
Publicado: (2017)

SARS-CoV-2 Vaccines: Status Report
por: Amanat, Fatima, et al.
Publicado: (2020)

Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model
por: Amanat, Fatima, et al.
Publicado: (2020)

Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model
por: Amanat, Fatima, et al.
Publicado: (2021)

Cross-Reactive Antibodies Binding to the Influenza Virus Subtype H11 Hemagglutinin
por: Strohmeier, Shirin, et al.
Publicado: (2019)

Prevalence of SARS-CoV-2 Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in New York City
por: Mansour, Mayce, et al.
Publicado: (2020)

Cross-reactive antibodies binding to H4 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model
por: Amanat, Fatima, et al.
Publicado: (2019)

Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans
por: Stadlbauer, Daniel, et al.
Publicado: (2017)

Monoclonal antibodies targeting the influenza virus N6 neuraminidase
por: Strohmeier, Shirin, et al.
Publicado: (2022)

Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain
por: Altomare, Clara G., et al.
Publicado: (2022)

Immunological imprinting of the antibody response in COVID-19 patients
por: Aydillo, Teresa, et al.
Publicado: (2021)

Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model
por: Duehr, James, et al.
Publicado: (2020)

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
por: Jangra, Sonia, et al.
Publicado: (2021)

Long-term Persistence of Neutralizing Antibodies to SARS-CoV-2 Following Infection
por: Wisnivesky, Juan P., et al.
Publicado: (2021)

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
por: Van Oekelen, Oliver, et al.
Publicado: (2021)

Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study
por: Wajnberg, Ania, et al.
Publicado: (2020)

At the Crossroads of Inflammation and Tumorigenesis
por: Cordon-Cardo, Carlos, et al.
Publicado: (1999)

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate
por: Sun, Weina, et al.
Publicado: (2020)

Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination
por: Amanat, Fatima, et al.
Publicado: (2023)

Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies
por: Krähling, Verena, et al.
Publicado: (2021)

Applications of array technology: identification of molecular targets in bladder cancer
por: Sánchez-Carbayo, M, et al.
Publicado: (2003)

Development of an Indirect ELISA Based on Spike Protein to Detect Antibodies against Feline Coronavirus
por: Dong, Bo, et al.
Publicado: (2021)

SARS-CoV-2 Infection Risk Among Active Duty Military Members Deployed to a Field Hospital — New York City, April 2020
por: Clifton, Guy T., et al.
Publicado: (2021)

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
por: Jangra, Sonia, et al.
Publicado: (2021)

Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests
por: De Marco Verissimo, Carolina, et al.
Publicado: (2021)

A Quantitative ELISA Protocol for Detection of Specific Human IgG against the SARS-CoV-2 Spike Protein
por: Vernet, Rémi, et al.
Publicado: (2021)

Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses
por: Amanat, Fatima, et al.
Publicado: (2018)

A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice
por: Strohmeier, Shirin, et al.
Publicado: (2022)

Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity
por: Phelan, Thomas, et al.
Publicado: (2021)

Use of recombinant S1 spike polypeptide to develop a TCoV-specific antibody ELISA
por: Gomaa, Maged H., et al.
Publicado: (2009)

Novel correlates of protection against pandemic H1N1 influenza A virus infection
por: Ng, Sophia, et al.
Publicado: (2019)

A Quantitative ELISA to Detect Anti-SARS-CoV-2 Spike IgG Antibodies in Infected Patients and Vaccinated Individuals
por: Luo, Ji, et al.
Publicado: (2022)

Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike
por: Wilson, Patrick, et al.
Publicado: (2021)

Inclusion of MERS‐spike protein ELISA in algorithm to determine serologic evidence of MERS‐CoV infection
por: Trivedi, Suvang, et al.
Publicado: (2017)

Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance
por: Freeman, Brandi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qlkd63k1f8mhnf5c3oee5n160m